The Investigational antiviral drug remdesivir by Gilead Sciences Inc (NASDAQ:GILD) was approved by US Food and Drug Administration (FDA) for emergency use in COVID-19 patients and becomes the first drug supported by early clinical information to be made available to combat the novel coronavirus.
This emergency use authorization (EUA) enables broader use of Remdesivir to treat patients who are hospitalized and having severe COVID-19 disease in the US.
Moreover, the Company disclosed that the optimal dose and duration of treatment for remdesivir in COVID-19 patients is still not known. Under this authorization, the ten day duration is recommended for patients who require invasive mechanical ventilation and/or extracorporeal membrane oxygenation (ECMO) and the five day dosing regimen is suggested for patients who do not require invasive mechanical ventilation and/or ECMO.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.